|  | Galcanezumab |
---|
Placebo n/N (%) | 120 mg n/N (%) | 240 mg n/N (%) |
---|
Systolic blood pressurea |
 Low | 7/1399 (0.5) | 3/698 (0.4) | 8/706 (1.1) |
 High | 40/1332 (3.0) | 22/672 (3.3) | 24/674 (3.6) |
 PCS high | 1/1409 (0.1) | 1/704 (0.1) | 0/708 (0.0) |
 Sustained | 7/1297 (0.5) | 2/658 (0.3) | 1/657 (0.2) |
Diastolic blood pressureb |
 Low | 6/1404 (0.4) | 2/704 (0.3) | 8/709 (1.1) |
 High | 83/1292 (6.4) | 51/653 (7.8) | 46/652 (7.1) |
 PCS high | 8/1402 (0.6) | 4/703 (0.6) | 5/704 (0.7) |
 Sustained | 15/1260 (1.2) | 9/639 (1.4) | 6/637 (0.9) |
Pulsec |
 Low | 5/1403 (0.4) | 1/700 (0.1) | 2/707 (0.3) |
 High | 32/1398 (2.3) | 13/702 (1.9) | 15/705 (2.1) |
 Sustained | 1/1361 (0.1) | 0/688 (0.0) | 1/687 (0.2) |
- Abbreviations: bpm Beats per minute, N Number of patients in the analysis population, n Number of patients within each specific category, PCS Possibly clinically significant
- aFor systolic blood pressure: treatment-emergent low ≤90 mmHg with ≥20 mmHg decrease; treatment-emergent high ≥140 mmHg with ≥20 mmHg increase; PCS high ≥180 mmHg with ≥20 mmHg increase; sustained elevation ≥140 mmHg with ≥20 mmHg increase for 2 consecutive office visits
- bFor diastolic blood pressure: treatment-emergent low ≤50 mmHg with ≥10 mmHg decrease; treatment-emergent high ≥90 mmHg with ≥10 mmHg increase; PCS high ≥105 mmHg with ≥15 mmHg increase; sustained elevation ≥90 mmHg with ≥10 mmHg increase for 2 consecutive office visits
- cFor pulse: treatment-emergent low < 50 bpm with ≥15 bpm decrease; treatment-emergent high > 100 bpm with ≥15 bpm increase; sustained elevation > 100 bpm with ≥15 bpm increase for 2 consecutive office visits